8220;we honed in on that number 400 million in business school
for a decade, as small-molecule generics have gone over the patent cliff, drug companies have clamoured to
offer next-generation versions of biotech drugs, called ldquo;biosimilarsrdquo;,
for a decade, as small-molecule generics have gone over the patent cliff, drug companies have clamoured to
offer next-generation versions of biotech drugs, called ldquo;biosimilarsrdquo;,
for a decade, as small-molecule generics have gone over the patent cliff, drug companies have clamoured to
offer next-generation versions of biotech drugs, called ldquo;biosimilarsrdquo;,